Articles tagged with Blood Cancer
Scientists at Barts Cancer Institute have identified a molecule called focal adhesion kinase (FAK) that signals the body to repair itself after chemotherapy or radiotherapy. Removing FAK from blood vessels in melanoma and lung cancer models made treatments more effective, suggesting that targeting this molecule could boost cancer therapy.
A large population-based study of European adults with blood cancers found that regional differences in treatment and care quality contribute to varying survival rates. The study analyzed data from 30 cancer registries covering all patients diagnosed in 20 European countries between 1997 and 2008.
A team of researchers at UT Arlington has developed a low-cost, non-invasive device to detect bladder cancer cells in urine. The device uses nanotechnology and can identify as few as two cancer cells in a full liter of urine, making it a promising tool for early detection.
Researchers at St. Joseph's Hospital and Medical Center discovered a new treatment for ovarian cancer that improves response rates and prolongs time until cancer recurrence. Trebananib, a peptide-Fc fusion protein, targets angiogenesis by inhibiting angiopoietin 1 and 2 binding to the Tie2 receptor.
A study found that childhood cancer survivors were hospitalized more often and for longer durations than the general population, with conditions like blood disorders and infections leading to hospitalizations. The study highlights the need for regular cancer-focused healthcare to identify health problems throughout their lives.
Researchers have developed a lab-on-a-chip platform capable of detecting protein cancer markers in blood at extremely low concentrations, enabling early diagnoses and treatment monitoring. The device's high sensitivity and portability make it an attractive tool for future cancer treatments.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a new epigenetic mechanism that distinguishes normal blood stem cells from blood cancers. This finding holds promise for developing targeted treatments that preserve healthy stem cells while killing leukemia cells.
A recent study published in Nature Genetics found a correlation between the loss of the Y chromosome in blood cells and both a shorter life span and higher mortality from cancer in other organs. Men who had lost the Y chromosome in a large proportion of their blood cells had a lower survival rate, irrespective of cause of death.
Researchers at Stanford Medicine have developed a highly sensitive and specific blood test that can accurately identify stage-1 lung cancer patients and detect rare cancer mutations. The CAPP-Seq technique analyzes tumor DNA in the blood to provide non-invasive monitoring of cancer progression and treatment responses.
A new study identified genetic variants associated with increased risk of bladder cancer recurrence. Inheriting certain DNA sequences may affect a patient's prognosis, allowing physicians to tailor surveillance and treatment plans.
Researchers discover MGA controls expression of Bone Morphogenetic Proteins, a crucial step in bone development, and may contribute to tumor formation in adults. The study suggests that MGA's dysfunction could lead to chronic lymphocytic leukemia.
Scientists have discovered two novel genes linked to angiosarcoma, a rare and aggressive cancer of blood vessels. The study found that these genes are mutated in nearly 40% of cases, suggesting potential new targets for treatment.
Researchers at Dana-Farber Cancer Institute found that the normal enzyme SYK pairs with mutated FLT3 to promote AML progression and resistance to treatment. Combination therapy involving SYK and FLT3 inhibitors showed significant promise in treating AML.
Researchers at University of British Columbia have discovered a potential new treatment for Paroxysmal nocturnal hemoglobinemia (PNH), a rare blood cancer that causes red blood cells to become vulnerable to the body's complement immune system. The treatment, aurin tricarboxylic acid (ATA), restores blood cell resistance and may also of...
Scientists at MD Anderson Cancer Center discovered that exosomes, tiny particles shed by cancer cells, contain the entire genetic blueprint of cancer cells. This finding could lead to a blood test that detects cancer gene defects and helps physicians treat patients earlier.
Researchers at Cornell University have discovered a new way to destroy metastasizing cancer cells by hitching killer proteins to white blood cells. The treatment, which uses E-selectin and TRAIL proteins, was found to be nearly 100% effective in killing cancer cells in laboratory tests.
Pediatric leukemia patients can now safely receive intravenous infusions of a reformulated chemotherapy agent, allowing for less frequent treatment and reduced pain. The study found similar efficacy and toxicity profiles between the IV PEG-asparaginase and IM native formulations.
Researchers have made significant strides in expanding transplant eligibility and improving long-term success rates, particularly for older patients. Studies have shown that haploidentical transplants and cord blood cells can be viable alternatives to fully matched donors.
A gene therapy trial has shown promising early results for the 'bubble boy' disease, with 8 out of 9 children treated well. The study used haploidentical transplants and high-dose post-transplantation cyclophosphamide to improve outcomes for patients who were previously ineligible due to a lack of matching donors.
A large study found a significant association between a history of airborne allergies, particularly to plants, grass, and trees, and an increased risk of hematologic malignancies in women. The study suggests that chronic immune stimulation may play a role in the development of blood cancers in women.
A large study of over 30 years found that eating a daily handful of nuts significantly reduces the risk of death from any cause. The study also found that regular nut-eaters were more slender than those who didn't eat nuts, contradicting a common worry about weight gain.
Researchers at Dana-Farber Cancer Institute have identified a protein that increases with endurance exercise and boosts brain health by promoting the growth of new nerves involved in learning and memory. The discovery provides a molecular pathway for exercise's effects on cognitive function, particularly in older adults.
Researchers at NYU Langone are leading a $6.25 million, five-year research initiative to find targeted treatments for children with acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. The project aims to improve the cure rate and reduce mortality rates among ALL patients.
A new survey of nearly 5,000 tumor samples has identified 140 regions with scrambled genetic code believed to contain many undiscovered cancer genes. The mapping gives researchers a starting point to search for oncogenes and tumor-suppressor genes.
A new drug, CMX001, has been shown to prevent a common and sometimes severe viral disease in patients receiving stem-cell transplants. The study found that patients taking the drug were 90% less likely to develop cytomegalovirus (CMV) infection than those taking a placebo.
Researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice. These non-replicating particles, derived from rhabdovirus, work by direct cytolysis and induction of antitumor immunity, showing promise as a new therapy for leukemia.
A study by Karoline Kollmann and colleagues reveals CDK6's role in regulating tumour growth while also promoting blood vessel formation. The researchers found that a mutant form of CDK6 retains its ability to regulate expression despite losing kinase function.
Researchers have identified glycolysis as a key mechanism for endothelial cell energy production and blood vessel formation. Blocking glycolysis could prevent excessive angiogenesis in diseases like cancer, offering new therapeutic options.
Researchers discovered a new molecular pathway causing heart failure and showed that JQ1 blocks this pathway to protect the heart. The compound works within the cell's nucleus, preventing damaging stress responses.
A new study found that regions near petroleum refineries and manufacturing plants releasing benzene have significantly higher non-Hodgkin lymphoma incidence rates. The risk of the disease decreases with increasing distance to these facilities.
Researchers have discovered that cancer cells can fuse with blood cells, enabling them to travel through the body and seed new tumors. This breakthrough has major implications for treating metastatic cancers.
A new study found that DNA abnormalities, specifically clonal mosaic events, are more common in people with type 2 diabetes than the general population. This increase in CMEs may partly explain why individuals with type 2 diabetes have a higher risk of blood cancers like lymphoma and leukaemia.
A new analysis found that African Americans with chronic lymphocytic leukemia present with advanced disease and have shorter survival times than Caucasians. The study suggests that biological factors may account for racial disparities in cancer survival.
Researchers will study pediatric sarcomas, a rare and aggressive form of cancer affecting 11% of all childhood cancers, with the goal of developing new therapies. The project aims to improve outcomes for children with advanced or metastatic disease, who have limited success with current treatments.
A study by Dana-Farber Cancer Institute researchers found that active surveillance and watchful waiting are safe alternatives to initial treatment for men with low-risk prostate cancers. These strategies can lead to better quality of life and reduced healthcare costs, with some patients experiencing up to 13 months additional quality-a...
Researchers have found antibodies against the human papillomavirus (HPV) that may help predict individuals at risk of HPV-related oropharyngeal cancer. The study found that these antibodies were detectable in nearly 35% of patients with cancer, compared to less than 1% of those without cancer.
The Leukemia & Lymphoma Society (LLS) and Dana-Farber Cancer Institute are partnering to establish a network of sites for clinical trial testing in community oncology settings. This partnership aims to increase trial enrollment and advance innovative blood cancer therapies, ultimately saving lives.
A recent study revealed a new mutation in atypical chronic neutrophilic leukemia (CNL) patients, allowing doctors to prescribe targeted treatment ruxolitinib. The treatment brought significant improvements to the patient's health, including reduced white blood cell counts and normalized other blood counts.
Researchers used advanced amplification technology to detect abnormal DNA in blood samples from patients with gastrointestinal stromal tumors (GIST). The new blood test found secondary resistance mutations in the KIT gene, which were missed by traditional tissue analysis.
Researchers at UCLA refine their 'NanoVelcro' device to capture and analyze single cancer cells from patient blood, enabling 'liquid biopsies' for metastatic melanoma. The improved device allows doctors to tailor personalized treatment to specific patients.
Researchers found that women with ovarian cancer had higher blood calcium levels than those without the disease. The study suggests that high calcium levels may be a biomarker for early detection of ovarian cancer.
A recent study published in Mayo Clinic Proceedings found that microscopic hematuria is an unreliable indicator of urinary tract malignant tumors. The study developed a Hematuria Risk Index to predict cancer risk, identifying low-risk patients who may not need further evaluation and reducing unnecessary evaluations.
Dr. James Watson suggests that antioxidants in late-stage cancer cells can promote cancer progression, and that reducing antioxidant levels may be key to developing new anti-metastatic drugs. He calls for a faster timetable for researching this proposition.
Researchers found that people with Type 2 diabetes who received diabetes education after a cancer diagnosis had fewer visits to the emergency room and hospital admissions. They also tested their blood sugar levels more often, resulting in lower healthcare costs.
Researchers at Johns Hopkins Kimmel Cancer Center have created a test that combines blood DNA analysis with genome sequencing to detect cancers. The new approach was successful in identifying cancer-specific chromosome changes in the blood of patients, but may require larger clinical trials to determine its effectiveness.
A new study uses blood testing to predict cathepsin activity, enzymes accelerating diseases like atherosclerosis and cancer. The technique achieved high predictability, ranging from 90 to 95 percent, and may help develop personalized treatments for tissue-destructive diseases.
A study found that survivors of cervical, blood, and colorectal cancers experience poorer physical and mental health-related quality of life compared to those with other types of cancer. The analysis estimated that 3.3 million and 1.4 million US cancer survivors face below-average physical and mental health, respectively.
Researchers found a direct relationship between telomere length and pancreatic cancer risk: shorter telomeres increase the likelihood of developing the disease. The study used data from over 1,500 individuals, including those with pancreatic cancer and healthy controls, to demonstrate this link.
A new study found that men with high blood pressure, high blood sugar, and a high body mass index are more likely to die from prostate cancer. Researchers also discovered that combining these metabolic factors increases the risk of death, suggesting that lifestyle changes may help prevent this.
UK scientists have developed a new drug that primes the immune system to fight cancer, with promising early laboratory results showing it can lead to long-term survival in lymphoma patients. The treatment uses a chemical called R848, which signals to certain immune cells to attack cancer.
Dartmouth College researchers have found that variations in white blood cell patterns can help predict the onset of certain cancers and diagnose them. By analyzing methylation signatures in leukocytes, they discovered correlations between specific cancers and unique patterns of immune cell subsets.
Researchers discovered that MYC protein boosts existing gene expression, rather than turning genes on or off, leading to a universal amplifier effect. This understanding could lead to new therapeutic strategies for cancers, such as targeting MYC activity instead of eliminating it.
The Legacy Bead program at St. Jude Children's Research Hospital uses glass beads to mark treatment milestones, such as losing hair or completing chemotherapy. Patients and family members can use the beads to express their feelings and create a tangible way to share their experiences.
Researchers identified a specific HIF2α mutation in tumor cells of patients with rare cancers, offering clues about cancer cell metabolism. The finding may lead to new targets for cancer treatment development and improve understanding of the mechanisms behind the Warburg effect.
Drs. Blazar and June will present their lecture on adoptive T-cell therapy, which has potential to establish tolerance to hematopoietic or solid organs allografts, treat autoimmunity, and promote immunity to cancer and chronic infection. The researchers have made significant contributions to advancing the field of BMT.
Researchers create super-sensor using nanoscale gold spheres to detect single samples of the smallest known viruses. The sensor uses 'whispering gallery mode' to measure precise frequency changes, allowing for accurate detection and sizing of viruses.
A team of scientists from the University of Southampton will explore ways to prevent graft-vs-host disease (GVHD) and improve bone marrow transplants by stimulating donor T-cells to target cancerous cells while reducing immune system reactions.
A new approach using an HIV drug has significantly reduced the incidence of graft-versus-host disease (GvHD) in bone marrow transplant patients. The treatment redirects immune cells away from vital organs, reducing the risk of GvHD without compromising the patient's ability to fight cancer.
Physiologists and neuropathologists from the University of Zurich have identified the origin of metastasis formation in intestinal cancer cells. Cancer cells manipulate specific doorman receptors on blood vessel endothelium to enter other organs via bloodstream.
Research established RNA Polymerase I (Pol I) activity as essential for cancer cell survival, and its inhibition with CX-5461 selectively activates p53 to kill tumors. The drug was shown to be 300 times more potent than non-genotoxic p53 activators.